Glenmede Trust’s 10x Genomics TXG Stock Holding History

Glenmede Trust’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,707	Closed	-$303K	–	1333
2022 Q2	$303K	Buy	6,707 +1,657	+33%	+$86K	﹤0.01%	1001
2022 Q1	$384K	Buy	5,050 +48	+1%	+$4.2K	﹤0.01%	973
2021 Q4	$745K	Sell	5,002 -3	-0.1%	-$460	﹤0.01%	820
2021 Q3	$728K	Sell	5,005 -148	-3%	-$25.4K	﹤0.01%	790
2021 Q2	$1.01M	Buy	+5,153	New	+$933K	0.01%	703

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's TXG Position: Q3 2022 in Review

Glenmede Trust sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 6,707 shares — an estimated $303K sold.

Glenmede Trust first reported a position in TXG in Q2 2021 and held it in 5 quarters. The position peaked at $1.01M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

Glenmede Trust reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
Glenmede Trust sold 6,707 10x Genomics shares in Q3 2022, an estimated $303K.
Glenmede Trust first reported a position in 10x Genomics in Q2 2021 and held it in 5 quarters.
Glenmede Trust's 10x Genomics position peaked at $1.01M in Q2 2021.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Glenmede Trust's 13F filing for Q3 2022, filed 16 Nov 2022.